DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0196286 A1 ARMER Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/0196286 A1 ARMER Et Al US 2010.0196286A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0196286 A1 ARMER et al. (43) Pub. Date: Aug. 5, 2010 (54) INHALATION DELIVERY METHODS AND A6II 3/54 (2006.01) DEVICES A63L/433 (2006.01) A6IR 9/12 (2006.01) (76) Inventors: Thomas A. ARMER, Cupertino, A 6LX 3/557 (2006.01) CA (US); Robert O. Cook, A 6LX 3/553 (2006.01) Hillsborough, NJ (US); Terry A 6LX 3/59 (2006.01) Alfredson, San Mateo, CA (US); A 6LX 3L/21995 (2006.01) Anthony Sun, New York, NY (US) A6II 3/343 (2006.01) A63L/404 (2006.01) Correspondence Address: A6II 3/472 (2006.01) MORRISON & FOERSTER LLP A 6LX 3/553 (2006.01) 7SS PAGE MILL RD A63L/506 (2006.01) PALO ALTO, CA 94304-1018 (US) A6IP 25/22 (2006.01) A6IP 25/24 (2006.01) (22) Filed: Dec. 1, 2009 (52) U.S. Cl. ........... 424/45: 514/396; 514/401; 514/617; 514/632: 514/183: 514/227.2: 514/362; 514/220; Related U.S. Application Data 514/221; 514/259.31; 514/249; 514/468; (60) Provisional application No. 61/119,015, filed on Dec. 514/419:514/307: 514/211.13: 514/252.15 1, 2008. (57) ABSTRACT Publication Classification Methods, devices and kits for treating sleep disorders, anxiety (51) Int. Cl. disorders, and developmental disorders, and/or for inducing A 6LX 3L/395 (2006.01) an arousable state of sedation in a Subject, are described. For A6 IK 3/4164 (2006.01) example, inhalation methods, devices and kits for treating A6 IK 3/468 (2006.01) insomnia, anxiety and/or ADHD using one or more C2-adr A6 IK3I/I65 (2006.01) energic agonists such as dexmedetomidine or clonidine are A6 IK3I/55 (2006.01) described. US 2010/0196286 A1 Aug. 5, 2010 NHALATION DELVERY METHODS AND the counter and does not seem to induce dependence, but its DEVICES effectiveness may decrease over time. Additionally, it may result in next-day sedation. CROSS-REFERENCE TO RELATED 0006. One specific form of insomnia is middle-of-the APPLICATIONS night insomnia (or “MOTN insomnia'). People suffering 0001. This application claims the benefit of U.S. Provi from MOTN insomnia experience difficulty returning to sional Application No. 61/119,015, filed Dec. 1, 2008, the sleep after awakening in the middle of their normal sleep disclosure of which is herein incorporated by reference in its period (which, it should be noted, may not necessarily be at entirety. night (e.g., as in the case of a shift worker)). While they may not have problems initially falling asleep, they wake up prior FIELD to their intended wake time. Because it disrupts normal sleep patterns, MOTN insomnia can result in fatigue following the 0002 Methods and devices for treating sleep disorders, normal sleep period. One or more of the above treatments anxiety disorders, and/or developmental disorders, and/or for may be unsuitable for treating MOTN insomnia. For inducing an arousable state of sedation in a subject (e.g., for example, the treatment or treatments may be slow to induce a perioperative, diagnostic, or non-Surgical procedure), are sleep and/or may require administration prior to about seven described herein. More specifically, inhalation methods and to nine hours in bed to avoid residual sleepiness after the devices for inducing an arousable state of sedation in a Sub normal wake-up time. Also, Some of the above-described ject, and/or for treating insomnia (e.g., MOTN insomnia), hypnotics may be administered prophylactically, which may anxiety, and/or attention deficit disorders (e.g., Attention result in unnecessary medication and/or overmedication. Deficit Hyperactivity Disorder, or ADHD) using one or more Moreover, it may be undesirable to have to self-administer a C2-adrenergic agonists (e.g., dexmedetomidine, medetomi pill or injection in the middle of the night to treat insomnia. dine, clonidine, guanfacine, etc.) are described herein. 0007 Another common form of insomnia is sleep onset insomnia, which is estimated to afflict approximately 10% of BACKGROUND the population in the United States. A person suffering from 0003 Sleep disorders (e.g., insomnia), anxiety disorders sleep onset insomnia is not able to fall asleep upon retiring. (e.g., panic disorder), and developmental disorders (e.g., The sleepless person may be restless (often for hours) and/or Attention-Deficit Hyperactivity Disorder, or ADHD) affect anxious, and may experience mental processing of daily millions of people. For example, it is estimated that insomnia activities which exacerbates the insomnia. Sleep onset may affects about 60-70 million Americans. Sleep, anxiety, and be induced by taking one or more medications in advance of developmental disorders can have a significant negative retiring (e.g., one hour prior to retiring). However, this may impact on quality of life, compromising the health, general interfere with the person's evening schedule or routine. More well-being, and/or safety of the person suffering from the over, taking Such medications in advance of retiring has led to disorder. Attention deficit disorders, e.g., ADHD, affect both morbidity, particularly in the form of hip fractures from adults and children, lowering their quality of life and produc drowsiness-induced falls. tivity. In some instances, a person may suffer from more than 0008 Sleep maintenance insomnia is another form of one of these disorders. For example, a person may suffer from sleeplessness. In the case of sleep maintenance insomnia, the both a sleep disorder and an anxiety disorder (e.g., with one Subject has difficulty falling asleep and remaining asleep for disorder causing the other). a prolonged period of normal sleep cycles. This type of 0004 Insomnia involves a persistentinability to fall asleep insomnia leaves the Subject chronically fatigued and unable or persistent difficulty in falling asleep and/or remaining to restore normal sleep patterns. Many of the therapeutic asleep during normal sleep times. A persistentinability to fall agents used to treat sleep maintenance insomnia have long asleep is more specifically referred to as sleep onset insomnia, half-lives, and therefore have long duration of effect (e.g., while the inability to remain asleep is more specifically usually 5-6 or more hours of non-arousable sedation). Such referred to as sleep maintenance insomnia. Insomnia may be long duration of effect can result in a morning "hangover. transient (e.g., lasting for days to weeks), acute (e.g., lasting with associated reduction in cognitive ability during waking for several weeks to several months), or chronic (e.g., lasting hours. Moreover, the use of long-acting agents may result in for years). Insomnia may be caused by, for example, certain disrupted sleep quality (sleep cycle disruption), and may also drugs and/or stimulants (e.g., caffeine), hormonal fluctua cause sleep-walking, sleep-eating and/or sleep-driving. tions, stress, anxiety, depression, and/or neurological disor While some benzodiazepineagents with short half-lives may ders, among other factors. be used, they can precipitate withdrawal symptoms, in addi 0005 Insomnia may be treated using drugs in the form of tion to causing amnesia and/or habitualization. In view of the pills, capsules, fast-melt tablets or injections. For example, above, it would be desirable to provide a rapidly-acting agent sedative hypnotic drugs such as benzodiazepines have been that does not have a prolonged duration of effect, and that has used to treatinsomnia for many years. Examples of benzodi minimal adverse side effects. It would be particularly desir azepines include temazepam (e.g., Restoril(R), flunitrazepam able to provide a rapidly-acting sleep maintenance agent that (e.g., Rohypnol (R), triazolam (e.g., Halcion.R.), flurazepam has minimal or no adverse effect on sleep cycle, and that does (e.g., Dalmane(R), nitrazepam (e.g., Mogadon(R), and mida not provide a waking hour sedative hangover. Zolam (e.g., Versed R). Non-benzodiazepine agents also have 0009 Anxiety disorders are psychological and/or physi been used to treat insomnia and include, for example, Zolpi ological disorders that may result in a person experiencing dem (e.g., Ambien R and Ambien CRR), Zaleplon (e.g., anger, fear, apprehension, and/or worry. Anxiety may result in Sonata(R), and eSZopiclone (e.g., Lunesta(R). In some cases, physical effects, such as heart palpitations, nausea, chest pain, the antihistamine diphenhydramine (e.g., Benadryl R) has shortness of breath, stomachaches, headaches, Sweating, been used as a sleep aid. Diphenhydramine is available over trembling, diarrhea, chills, pupillary dilation, hot flashes, US 2010/0196286 A1 Aug. 5, 2010 Sudden tiredness, hypertension, and/or digestion problems. acting medication that could induce sleep or sedation within There are many different types of anxiety disorders, including about 30 minutes or less of administration may avoid the generalized anxiety disorder, panic disorder, phobias Such as schedule limitations of current remedies, while minimizing agoraphobia, Social anxiety disorder, obsessive-compulsive the potential for drowsiness-induced injury. Such medication disorder, post-traumatic stress disorder, and separation anxi could be taken immediately before or after the person has ety disorder. An additional form of anxiety is hospital proce retired for the night, thus assuring that the person is already in dural anxiety, such as that experienced by a patient prior to a bed when the sedation takes effect. procedure (e.g., needle use, magnetic resonance imaging 0014. It would also be desirable to be able to induce an (MRI) scanning, etc.). Some anxiety sufferers experience arousable state of sedation in a Subject (e.g., for a periopera panic attacks, which usually come with little or no warning. A tive, diagnostic and/or non-Surgical procedure). A method of person experiencing a panic attack may suffer from head inhaled sedation can be especially useful prior to Surgical aches, heart palpitations, dizziness, insomnia and/or chest procedures for pediatric patients.
Load more

Recommended publications
  • By ANDREA PETERSEN Getty Images for Those Who Have Trouble
    By ANDREA PETERSEN Getty Images For those who have trouble sleeping, there may soon be new ways to summon the sandman. Several pharmaceutical companies are working on new approaches to treat insomnia. The compounds are meant to work differently than current leading sleep aids such as Ambien and Lunesta, which, while generally safe, can have troubling side effects because they act on many areas of the brain. By contrast, many of the drugs being developed target particular systems responsible for sleep and wakefulness. The hope is that they will have fewer side effects and less potential for addiction and cognition problems the next day. New drugs are in the works to treat insomnia, which affects 10% to 30% of Americans (and more women than men). Andrea Peterson explains. About 30% of American adults have insomnia symptoms each year, scientific studies estimate. Some 10% of the population has chronic insomnia, which is generally defined as having difficulty sleeping at least three times a week for a month or more. Chronic insomnia sufferers also feel tired, cranky or foggy-headed during the day. Insomnia comes in various forms. Some people have a tough time falling asleep and others wake in the middle of the night and have trouble getting back to sleep. Some people rise for the day too early. Insomnia can increase the risk for other conditions, including heart disease, diabetes and depression. Merck & Co. is investigating a compound that inhibits the action of orexin receptors, which in turn interferes with the activity of orexin, a chemical in the brain that produces alertness.
    [Show full text]
  • 204569Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204569Orig1s000 MEDICAL REVIEW(S) Cross Discipline Team Leader Review 3. CMC/Device Dr. Khairuzzaman found the drug product portion of the NDA to be acceptable, and without need for phase 4 commitments. Dr. Sapru’s review stated that with the exception of a pending issue concerning the control of potential genotoxic impurity (b) (4) the NDA was approvable in terms of drug substance. Dr. Suarez found that the NDA was acceptable from a biopharmaceutics perspective. The Office of Compliance issuance of an acceptable recommendation for drug substance manufacturing and testing facilities was pending at the time of this review. 4. Nonclinical Pharmacology/Toxicology Dr. Richard Siarey completed the primary nonclinical review, and Dr. Lois Freed completed a supervisory memo. Dr. Siarey’s overall conclusion was that from a nonclinical perspective, approval of the suvorexant NDA was recommended. However, he found evidence that catapelxy was observed in dogs exposed to MK-4305 (suvorexant) near Tmax, although he concluded that additional information could have been gained by studying the drug in an experimental model that has been used for diagnosing cataplexy in dogs. Dr. Siarey suggested that since cataplexy occurred in dogs near Tmax, a time at which if used for insomnia patients would ordinarily be in bed, safety concern for humans was reduced. Dr. Siarey also found that the neurobehavioral assessment in the pre- and post-natal developmental study was not complete, as the passive avoidance tests was performed too early in development, while learning/acquisition tests and retention/memory tests were not conducted.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates Et Al
    US008598119B2 (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates et al. (45) Date of Patent: Dec. 3, 2013 (54) METHODS AND COMPOSITIONS FOR AOIN 43/00 (2006.01) SLEEP DSORDERS AND OTHER AOIN 43/46 (2006.01) DSORDERS AOIN 43/62 (2006.01) AOIN 43/58 (2006.01) (75) Inventors: Sharon Mates, New York, NY (US); AOIN 43/60 (2006.01) Allen Fienberg, New York, NY (US); (52) U.S. Cl. Lawrence Wennogle, New York, NY USPC .......... 514/114: 514/171; 514/217: 514/220; (US) 514/229.5: 514/250 (58) Field of Classification Search (73) Assignee: Intra-Cellular Therapies, Inc. NY (US) None See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 215 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 12/994,560 6,552,017 B1 4/2003 Robichaud et al. 2007/0203120 A1 8, 2007 McDevitt et al. (22) PCT Filed: May 27, 2009 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O09/OO3261 S371 (c)(1), WO WOOOf77OO2 * 6, 2000 (2), (4) Date: Nov. 24, 2010 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2009/145900 Rye (Sleep Disorders and Parkinson's Disease, 2000, accessed online http://www.waparkinsons.org/edu research/articles/Sleep PCT Pub. Date: Dec. 3, 2009 Disorders.html), 2 pages.* Alvir et al. Clozapine-Induced Agranulocytosis. The New England (65) Prior Publication Data Journal of Medicine, 1993, vol. 329, No. 3, pp. 162-167.* US 2011/0071080 A1 Mar.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Journal of Psychopharmacology
    Journal of Psychopharmacology http://jop.sagepub.com/ British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders SJ Wilson, DJ Nutt, C Alford, SV Argyropoulos, DS Baldwin, AN Bateson, TC Britton, C Crowe, D-J Dijk, CA Espie, P Gringras, G Hajak, C Idzikowski, AD Krystal, JR Nash, H Selsick, AL Sharpley and AG Wade J Psychopharmacol 2010 24: 1577 originally published online 2 September 2010 DOI: 10.1177/0269881110379307 The online version of this article can be found at: http://jop.sagepub.com/content/24/11/1577 Published by: http://www.sagepublications.com On behalf of: British Association for Psychopharmacology Additional services and information for Journal of Psychopharmacology can be found at: Email Alerts: http://jop.sagepub.com/cgi/alerts Subscriptions: http://jop.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav Citations: http://jop.sagepub.com/content/24/11/1577.refs.html Downloaded from jop.sagepub.com at University of Otago Library on March 11, 2011 Original Paper British Association for Psychopharmacology consensus statement on evidence-based Journal of Psychopharmacology treatment of insomnia, parasomnias and 24(11) 1577–1600 ! The Author(s) 2010 circadian rhythm disorders Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881110379307 jop.sagepub.com SJ Wilson1, DJ Nutt2, C Alford3, SV Argyropoulos4, DS Baldwin5, AN Bateson6, TC Britton7, C Crowe8, D-J Dijk9, CA Espie10, P Gringras11, G Hajak12, C Idzikowski13, AD Krystal14, JR Nash15, H Selsick16, AL Sharpley17 and AG Wade18 Abstract Sleep disorders are common in the general population and even more so in clinical practice, yet are relatively poorly understood by doctors and other health care practitioners.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Un Novedoso Enfoque Para El Diseño De Fármacos Antimicrobianos Asistido Por Computadora
    TOMOCOMD-CARDD: Un Novedoso Enfoque para el Diseño de Fármacos Antimicrobianos Asistido por Computadora Autora: Yasnay Valdés Rodríguez. Tutores: Prof. Dr. Yovani Marrero Ponce. Prof. MSc. Ricardo Medina Marrero. 2005-2006 La ignorancia afirma o niega rotundamente; la ciencia duda… Voltaire (1694-1778) Quiero dedicar este trabajo a todas aquellas personas que me aprecian y desean lo mejor para mi, especialmente a mis padres. A mi padre Dedico este trabajo con mucho amor, por hacerme comprender que siempre se puede llegar mas lejos, y que no hay nada imposible, solamente hay que luchar... A mi madre Por su infinita bondad, por su sacrificio inigualable. A mis familiares Por todo su apoyo y ayuda que me han mostrado incondicionalmente. A mi hermano Por ser mi fuente de inspiración. A la humanidad “...porque si supiera que el mundo se acaba mañana, yo, hoy todavía, plantaría un árbol” Quiero agradecer a todas aquellas personas que me han ayudado a realizar este sueño: A mis padres por todo el sacrificio realizado, y aún parecerles poco, los amo mucho. A mi madre por estar siempre a mi lado en los buenos y malos momentos ayudándome a levantarme en cualquier recaída. A mi padre por guiarme en la vida y brindarme sus consejos siempre útiles, por darme fuerza y vitalidad. A mi mayor tesoro, mi hermano, que me alumbra de esperanza día a día. A mis tías y primos que me ayudaron mucho, aún estando lejos. A mi novio que me apoyo en todas mis decisiones y con paciencia supo ayudarme. A mis tutores y cotutores que siempre me dieron la mano; especialmente a Yovani por su paciencia, a quien debo gran parte de mi formación como profesional por sus exigencias.
    [Show full text]
  • Emerging Anti-Insomnia Drugs: Tackling Sleeplessness and the Quality of Wake Time
    REVIEWS Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time Keith A. Wafford* and Bjarke Ebert‡ Abstract | Sleep is essential for our physical and mental well being. However, when novel hypnotic drugs are developed, the focus tends to be on the marginal and statistically significant increase in minutes slept during the night instead of the effects on the quality of wakefulness. Recent research on the mechanisms underlying sleep and the control of the sleep–wake cycle has the potential to aid the development of novel hypnotic drugs; however, this potential has not yet been realized. Here, we review the current understanding of how hypnotic drugs act, and discuss how new, more effective drugs and treatment strategies for insomnia might be achieved by taking into consideration the daytime consequences of disrupted sleep. Primary insomnia Humans spend approximately one-third of their lifetime Insomnia is defined as difficulty in initiating and/or Patients who suffer from sleeping, but we still know relatively little about why this maintaining sleep. The incidence of insomnia in the gen- sleeplessness for at least process is so critical for every living animal. Current eral population is between 10–30%, and approximately 1 month that cannot be thinking suggests that waking activity is relatively 50% of the cases complain of serious daytime conse- attributed to a medical, dynamic in terms of using the body’s resources: breaking quences, such as inability to concentrate, reduced energy psychiatric or an environmental cause (such as drug abuse or down proteins, gathering information and expending and memory problems. When this persists for more medications).
    [Show full text]
  • WO 2010/065547 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 10 June 2010 (10.06.2010) WO 2010/065547 Al (51) International Patent Classification: (74) Agents: AMII, Lisa, A. et al.; Morrison & Foerster LLP, A61M 15/00 (2006.01) A61M 9/00 (2006.01) 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). A61M 16/00 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2009/066272 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 1 December 2009 (01 .12.2009) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (25) Filing Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (26) Publication Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (30) Priority Data: SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, 61/1 19,015 1 December 2008 (01 .12.2008) US TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US): MAP (84) Designated States (unless otherwise indicated, for every PHARMACEUTICALS, INC. [US/US]; 2400 Bayshore kind of regional protection available): ARIPO (BW, GH, Parkway, Suite 200, Mountain View, CA 94043 (US).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Long Acting, Reversible Veterinary Sedative and Analgesic And
    University of Kentucky UKnowledge Veterinary Science Faculty Patents Veterinary Science 7-11-2006 Long Acting, Reversible Veterinary Sedative and Analgesic and Method of Use Thomas Tobin University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/gluck_patents Part of the Veterinary Medicine Commons Recommended Citation Tobin, Thomas, "Long Acting, Reversible Veterinary Sedative and Analgesic and Method of Use" (2006). Veterinary Science Faculty Patents. 14. https://uknowledge.uky.edu/gluck_patents/14 This Patent is brought to you for free and open access by the Veterinary Science at UKnowledge. It has been accepted for inclusion in Veterinary Science Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [email protected]. US007074834B2 (12) United States Patent (10) Patent N0.: US 7,074,834 B2 Tobin (45) Date of Patent: Jul. 11, 2006 (54) LONG ACTING, REVERSIBLE VETERINARY 4,742,054 A 5/1988 Naftchi SEDATIVE AND ANALGESIC AND METHOD 4,950,648 A 8/1990 Raddatz et a1. OF USE 5,635,204 A * 6/1997 GevirtZ et a1. ............ .. 424/449 5,942,241 A 8/1999 Chasin et a1. (75) Inventor: Thomas Tobin, Lexington, KY (US) 5,958,933 A 9/1999 Naftchi (73) Assignee: University of Kentucky Foundation, OTHER PUBLICATIONS Lexington, KY (US) MEDLINE AN 20000025586, Veveris et al, Brit. J. Pharmacol, 128 (5), 1089-97, Nov. 1999, abstract.* ( * ) Notice: Subject to any disclaimer, the term of this Veterinary Pharmacology and Therapeutics, Adams, pp.
    [Show full text]